All lobbying filings

THE MADISON GROUP

Lobbying for NOVO NORDISK INC. · Pharmaceutical Company

Filing 2nd Quarter - Termination

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 18, 2025

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

New Jersey

Representation ended

May 31, 2025

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 5

Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Lobbying activity 2

Health Issues

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications, and (4) issues related to compounding and counterfeit drugs.

Medicare/Medicaid

Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.